Arvinas, Inc. (ARVN)
Automate Your Wheel Strategy on ARVN
With Tiblio's Option Bot, you can configure your own wheel strategy including ARVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARVN
- Rev/Share 5.1209
- Book/Share 8.3695
- PB 1.018
- Debt/Equity 0.0162
- CurrentRatio 5.6369
- ROIC -0.1571
- MktCap 625517909.0
- FreeCF/Share -5.4808
- PFCF -1.5677
- PE -8.5435
- Debt/Assets 0.0109
- DivYield 0
- ROE -0.1201
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ARVN | BofA Securities | Buy | Neutral | -- | $10 | Sept. 24, 2025 |
| Resumed | ARVN | Barclays | -- | Overweight | -- | $16 | Sept. 17, 2025 |
| Downgrade | ARVN | Leerink Partners | Outperform | Market Perform | -- | $9 | June 2, 2025 |
| Downgrade | ARVN | Truist | Buy | Hold | -- | $11 | May 5, 2025 |
| Downgrade | ARVN | Jefferies | Buy | Hold | -- | $10 | May 2, 2025 |
| Downgrade | ARVN | TD Cowen | Buy | Hold | -- | -- | May 2, 2025 |
| Downgrade | ARVN | Goldman | Buy | Neutral | $70 | $15 | March 13, 2025 |
| Downgrade | ARVN | Wedbush | Outperform | Neutral | $57 | $12 | March 12, 2025 |
| Downgrade | ARVN | Oppenheimer | Outperform | Perform | -- | -- | March 11, 2025 |
| Initiation | ARVN | BTIG Research | -- | Buy | -- | $69 | Dec. 10, 2024 |
News
Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Arvinas, Inc. (NASDAQ:ARVN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with the afternoon session.
Read More
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.
Read More
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.
Read More
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –
Read More
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma –
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 94.9% upside potential for Arvinas (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
ARVN ACTIVE INVESTIGATION: Lost Money on Arvinas, Inc.? Contact Levi & Korsinsky Now
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
ATTENTION ARVN SHAREHOLDERS: Investors Who Lost Money on Arvinas, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
An Investigation Has Commenced on Behalf of Arvinas, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ARVN Losses.
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVN
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
Arvinas, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ARVN
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Arvinas, Inc. (ARVN) Shareholders Who May Have Been Affected by Fraud
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Arvinas, Inc. (ARVN) Shareholders Who May Have Been Affected by Fraud
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Arvinas, Inc. (ARVN) Shareholders Who May Have Been Affected by Fraud
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
ARVN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Arvinas, Inc. Shareholders Who Lost Money
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
ARVN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Arvinas, Inc.
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About Arvinas, Inc. (ARVN)
- IPO Date 2018-09-27
- Website https://www.arvinas.com
- Industry Biotechnology
- CEO John G. Houston
- Employees 430